Pricing, access & reimbursement strategy

Building Sustainable Models for Affordable Patient Access

SouthBridge Advisory helps biopharma companies design affordable yet commercially viable pricing and reimbursement models that expand patient access to advanced therapies, particularly in low- and middle-income countries (LMICs). With deep experience across emerging markets, we balance payer sensitivities, regulatory requirements, and patient affordability to create strategies that deliver measurable impact.

Our approach

Sustainable Pricing Models

Developing value-based pricing frameworks that improve affordability without compromising commercial success.

Reimbursement Strategy

Designing reimbursement pathways tailored to payer systems in LMICs, ensuring therapies are accessible and adopted widely.

Market Access Roadmaps

Creating structured access strategies that combine regulatory alignment, stakeholder engagement, and patient-focused solutions.

Patient-Centric Affordability Programs

Integrating financial assistance and innovative PSPs to bridge the gap between therapy cost and patient ability to pay.

why partner with us?

Expanded patient access by 30% in LMICs through optimized pricing and reimbursement strategies.
Expertise in navigating complex payer environments and healthcare systems across Asia, the Middle East, and Latin America.
Proven success in balancing affordability with commercial viability for advanced therapies.
End-to-end execution support, from model design to stakeholder engagement.

Testimonial

People like us, officially

Trusted by biopharma leaders, medical experts, and investors worldwide for delivering real-world commercialization success in advanced therapies.

SouthBridge’s deep understanding of pricing and access challenges in emerging markets was instrumental in the successful launch of our biologic. Their execution-first approach set them apart from other consultants.

Biopharma Executive Emerging Markets

The team at SouthBridge bridged the gap between science and market strategy. Their KOL engagement framework helped us build strong advocacy and accelerate adoption of our cell therapy

Medical Affairs Director Global CGT Company

SouthBridge’s due diligence and market insights gave us the confidence to invest in a groundbreaking gene therapy. Their practical expertise ensured we had a clear roadmap for commercialization.

Investor Healthcare VC Fund